atezolizumab
roche
['atezo', 'sclc']
today at #asco22- final pfs analysis of tira+atezo+ce vs pbo+atezo+ce showed no benefit in pts with untreated es-sclc. final os analysis pending but interim analysis demonstrates no benefit. no new safety signals were identified, confirming the drug combination is tolerable 
Real time, on-demand personalized cancer education and support through our online educational platform